LEADER 00000cam a2200685Mu 4500 
001    on1202480440 
003    OCoLC 
005    20220114043859.0 
006    m     o  d         
007    cr cnu---unuuu 
008    201031s2020    si      o     ||| 0 eng d 
019    1200197704|a1202449622 
020    9811454078 
020    9789811454073|q(electronic book) 
035    (OCoLC)1202480440|z(OCoLC)1200197704|z(OCoLC)1202449622 
040    EBLCP|beng|cEBLCP|dEBLCP|dYDX|dUKAHL|dN$T|dOCLCF 
049    RIDW 
050  4 RM315 
066    |c(S 
082 04 615.78|223 
090    RM315 
245 00 Medicinal Chemistry of Drugs Affecting the Nervous System.
264  1 Singapore :|bBentham Science Publishers,|c2020. 
300    1 online resource (406 pages). 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
340    |gpolychrome|2rdacc 
347    text file|2rdaft 
490 1  Medicinal Chemistry for Pharmacy Students Ser. 
500    Description based upon print version of record. 
505 0  Cover -- Title -- Copyright -- End User License Agreement 
       -- Contents -- Preface -- List of Contributors -- Drugs 
       Affecting the Cholinergic System -- Cory R. Theberge1, Kim
       Lindsey-Goodrich2 and Ashok E. Philip3,* -- HISTORICAL 
       PERSPECTIVES -- INTRODUCTORY CONCEPTS -- Choline and 
       Acetylcholine -- Acetylcholine and Neurotransmission -- 
       Cholinergic Neurochemistry: ACh Biosynthesis, Storage, 
       Release, and Metabolism -- Cholinergic Receptors -- 
       Muscarinic and Nicotinic Subtypes -- Clinical Use of 
       Acetylcholine -- MUSCARINIC RECEPTOR AGONISTS -- 
       MUSCARINIC RECEPTOR ANTAGONISTS (ANTICHOLINERGICS) 
505 8  Donepezil (Aricept®) -- Pharmacokinetics -- Side effects/
       Drug Interactions -- Rivastigmine (Exelon®) 2000, Oral -- 
       2008, Patch -- Pharmacokinetics -- Side effects/Drug 
       Interactions -- Galantamine (Razadyne®) 2001 -- 
       Pharmacokinetics -- Side effects/Drug-interactions -- NMDA
       Receptor Antagonist: Memantine (Namenda®) 2003 -- 
       Pharmacokinetics -- Side effects/Drug interactions -- 
       Place in Therapy -- CASE STUDY -- What therapeutic 
       modifications would you make at this time and why? -- Drug
       Discovery Case Study -- The Quaternary Advantage -- 
       Ipratropium and the Kinetic Selectivity of Tiotropium 
505 8  STUDENT SELF STUDY GUIDE -- PRACTICE QUESTIONS -- NOTES --
       CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- 
       ACKNOWLEDGEMENTS -- REFERENCES -- Drugs Affecting 
       Adrenergic System -- M. O. Faruk1,* and Les Ramos2 -- 
       HISTORICAL BACKGROUND -- THE INTRODUCTORY CONCEPTS -- 
       Adrenergic Neurotransmitters -- Adrenergic Receptors (ARs)
       -- DRUGS AFFECTING ADRENERGIC SYSTEM: STRUCTURES, ACTIVITY,
       METABOLISM AND RELATED THERAPEUTIC CONSIDERATIONS -- The 
       Antiadrenergics Affecting Synthesis, Storage, or Release 
       of NE (Fig. 7) -- Metyrosine -- Reserpine -- Mechanism of 
       Action -- Pharmacokinetics 
520    The primary objective of this 4-volume book series is to 
       educate PharmD students on the subject of medicinal 
       chemistry. The book set serves as a reference guide to 
       pharmacists on aspects of the chemical basis of drug 
       action. Medicinal Chemistry of Drugs Affecting the Nervous
       System is the second volume of the series and it presents 
       8 chapters focusing on a comprehensive account of drugs 
       affecting the nervous system. The volume informs readers 
       about the medicinal chemistry of relevant drugs, which 
       includes the mechanism of drug action, detail structure 
       activity relationships and metabolism as w. 
590    eBooks on EBSCOhost|bEBSCO eBook Subscription Academic 
       Collection - North America 
650  0 Neuropharmacology.|0https://id.loc.gov/authorities/
       subjects/sh85091157 
650  0 Autonomic nervous system|0https://id.loc.gov/authorities/
       subjects/sh85090938|xEffect of drugs on.|0https://
       id.loc.gov/authorities/subjects/sh00004603 
650  0 Central nervous system|0https://id.loc.gov/authorities/
       subjects/sh85021906|xEffect of drugs on.|0https://
       id.loc.gov/authorities/subjects/sh00004603 
650  0 Pharmaceutical chemistry.|0https://id.loc.gov/authorities/
       subjects/sh85023026 
650  7 Neuropharmacology.|2fast|0https://id.worldcat.org/fast/
       1036458 
650  7 Autonomic nervous system.|2fast|0https://id.worldcat.org/
       fast/824152 
650  7 Central nervous system|xEffect of drugs on.|2fast|0https:/
       /id.worldcat.org/fast/850741 
650  7 Central nervous system.|2fast|0https://id.worldcat.org/
       fast/850724 
650  7 Pharmaceutical chemistry.|2fast|0https://id.worldcat.org/
       fast/1060115 
655  4 Electronic books. 
700 1  Faruk, M. O. 
700 1  Philip, Ashok E. 
776 08 |iPrint version:|aFaruk, M. O.|tMedicinal Chemistry of 
       Drugs Affecting the Nervous System|dSingapore : Bentham 
       Science Publishers,c2020|z9789811454059 
830  0 Medicinal Chemistry for Pharmacy Students Ser. 
856 40 |uhttps://rider.idm.oclc.org/login?url=https://
       search.ebscohost.com/login.aspx?direct=true&scope=site&
       db=nlebk&AN=2649039|zOnline ebook via EBSCO. Access 
       restricted to current Rider University students, faculty, 
       and staff. 
856 42 |3Instructions for reading/downloading the EBSCO version 
       of this ebook|uhttp://guides.rider.edu/ebooks/ebsco 
880    |6500-00/(S|aTherapeutic Evaluation of the Imidazoline α 
       Adrenergic Agonists 
880 8  |6505-00/(S|aGuanethidine and Guanadrel -- Direct-Acting 
       Sympathomimetic Agents -- The General Mechanism and SAR of
       β-Phenylethylamine Derivatives (Direct and Indirect Acting
       Agonists) -- Sar 1 -- Sar 2 -- Sar 3 -- Sar 4 -- Sar 5 -- 
       Sar 6 -- Sar 7 -- Sar 8 -- Sar 9 -- Therapeutic Evaluation
       of the β-Phenylethylamine Direct Acting Adrenergic 
       Agonists -- β2 Adrenergic Agonist and Cardiac Function -- 
       Long Acting β2-Adrenoceptor Agonists (LABAs) -- β3 
       Adrenergic Receptor Agonist -- The General SAR of 
       Imidazolines (α Adrenergic Agonist and Antagonists) -- Sar
       1 -- Sar 2 -- Sar 3 
880 8  |6505-00/(S|aAcetylcholinesterase (AChE) Inhibitors -- 
       Reversible Noncovalent Inhibitors -- Reversible Covalent 
       Inhibitors -- Irreversible Covalent Inhibitors -- 
       NEUROMUSCULAR BLOCKING AGENTS -- Depolarizing Muscle 
       Nicotinic Receptor Neuromuscular Blocking Agents -- Non-
       depolarizing Muscle Nicotinic Receptor Neuromuscular 
       Blocking Agents -- Ganglionic-Nicotinic Receptor Blocking 
       Agents -- TREATMENT OF ALZHEIMER'S DISEASE (AD) -- 
       Epidemiology -- Pathophysiology -- β-Amyloid Hypothesis --
       Cholinergic Hypothesis -- Other Hypothesis -- 
       Pharmacotherapy -- Acetyl Cholinesterase (AChE) Inhibitors
901    MARCIVE 20231220 
948    |d20220127|cEBSCO|tEBSCOebooksacademic NEW 6019|lridw 
994    92|bRID